Enhanced brain cells clear away dementia-related proteins

The new generation of Alzheimer's disease drugs—the first proven to change the course of the disease—typically extend independent living for patients by 10 months. Called monoclonal antibodies, they reduce the accumulation of a harmful protein, amyloid, in the brain and require high-dose, once- or twice-monthly infusions of the medication.